|Trade names||Vistogard, Xuriden|
|Main uses||Hereditary orotic aciduria, poisoning due to fluorouracil or capecitabine|
|Onset of action||Tmax = 2–3 hours|
|Metabolism||Pyrimidine catabolic pathway|
|Elimination half-life||2–2.5 hours|
|Chemical and physical data|
|Molar mass||370.314 g·mol−1|
|3D model (JSmol)|
Uridine triacetate, formerly known as vistonuridine, is a medication used to treat hereditary orotic aciduria and poisoning due to fluorouracil or capecitabine. For poisoning it should be used within 4 days and in an overdose may be used regardless of the presence of symptoms. It is taken by mouth.
Uridine triacetate was approved for medical use in the United States in 2015. It is not approved in Europe. In the United States it costs about 4,200 USD per 10 gram dose as of 2021. In the United States it is only available through specialty pharmacies. In Canada approval is required from the Health Canada Special Access Programme. Brand names include Vistogard and Xuriden.
For poisoning a dose of 10 gm four times per day for 5 days is typically used.
For hereditary orotic aciduria a dose of 60 mg/kg per day to a maximum of 8 gm per day is typically used.
Society and culture
The cost of the medication used to treat an overdose is about 84,000 USD in the United States as of 2021.
- "Uridine Triacetate Monograph for Professionals". Drugs.com. Archived from the original on 8 December 2019. Retrieved 13 September 2021.
- Saif, Muhammad Wasif (4 March 2019). "Uridine triacetate - an antidote in the treatment of 5-fluorouracil or capecitabine poisoning". Expert Opinion on Orphan Drugs. 7 (3): 95–103. doi:10.1080/21678707.2019.1591273.
- "Uridine Use During Pregnancy". Drugs.com. Archived from the original on 30 October 2020. Retrieved 13 September 2021.
- "FDA approves drug for genetic condition that affects 20 patients worldwide". The Pharmaceutical Journal. 2015. doi:10.1211/PJ.2015.20069307.
- "Vistogard Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 22 January 2021. Retrieved 13 September 2021.
- "BC Cancer Agency Management Guidelines Management of 5-fluorouracil (5FU) infusion overdose" (PDF). Archived (PDF) from the original on 8 February 2020. Retrieved 13 September 2021.
- "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65" (PDF). World Health Organization. p. 92. Archived (PDF) from the original on 18 May 2016. Retrieved 12 March 2017.
- "Xuriden- uridine triacetate granule". DailyMed. 16 December 2019. Archived from the original on 23 October 2020. Retrieved 20 October 2020.
- "Vistogard- uridine triacetate granule". DailyMed. 15 November 2018. Archived from the original on 23 October 2020. Retrieved 20 October 2020.
- "BTG Announces FDA Approval of Vistogard (Uridine Triacetate) as Antidote to Overdose and Early Onset, Severe, or Life-Threatening Toxicities from Chemotherapy Drugs 5-Fluorouracil (5-FU) or Capecitabine". BTG International Ltd. 11 December 2015. Archived from the original on 8 April 2017. Retrieved 12 March 2017.
- "Approved Drugs — Uridine Triacetate". U.S. Food and Drug Administration. Archived from the original on 13 March 2017. Retrieved 12 March 2017.